{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:44:04Z","timestamp":1793411044701,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AstraZeneca, China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Data on prevalence of programmed death ligand-1 (PD-L1) expression and its correlation with tumor biomarkers in Chinese patients with muscle-invasive urothelial bladder cancer (MIUBC) are scarce. We investigated the prevalence of PD-L1 expression, PD-L1 expression in tumor cells (TC) and immune cells (IC), and its correlation with tumor biomarkers (CD8+ T cells and tumor mutation burden [TMB]) in Chinese patients with newly diagnosed MIUBC (NCT03433924). Of 248 patients enrolled, 229 with PD-L1 data available were analysed. High PD-L1 expression (\u2265\u200925% of TC or IC with PD-L1 expression) was observed in 120 (52.4%) patients. 59 cases showed positive staining in \u2265\u200925% of TC, and 82 cases had positive staining in \u2265\u200925% of IC. High expression of CD8+ T cell and TMB (&gt;\u200910 mutations\/megabase) was observed in 44.5% and 54.1% patients, respectively. A positive correlation was observed between percentage of TC with membrane PD-L1 positivity and CD8+ T cells (0.34;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) and between IC with membrane PD-L1 positivity and CD8+ T cells (0.44;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). There is high prevalence of PD-L1 expression in Chinese patients with MIUBC, suggesting that a sizable subset of patients could benefit from immunotherapy. The correlation of PD-L1 expression with tumor biomarkers provide clues for mechanisms underlying the effects of biomarkers for predicting efficacy.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-67508-6","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T09:01:41Z","timestamp":1721466101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["PD-L1 expression and its correlation with tumor biomarkers in Chinese urothelial bladder cancer"],"prefix":"10.1038","volume":"14","author":[{"given":"Yu","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangjian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benkang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaogang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinchun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuize","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,20]]},"reference":[{"key":"67508_CR1","first-page":"15","volume":"8","author":"K Saginala","year":"2020","unstructured":"Saginala, K. et al. Epidemiology of bladder cancer. Med. Sci. (Basel) 8, 15 (2020).","journal-title":"Med. Sci. (Basel)"},{"key":"67508_CR2","unstructured":"Mohammadian, M. et al. Recent patterns of bladder cancer incidence and mortality: a global overview. North America 12."},{"key":"67508_CR3","unstructured":"WHO. Bladder cancer statistics | World Cancer Research Fund International. WCRF International https:\/\/www.wcrf.org\/cancer-trends\/bladder-cancer-statistics\/ (2020)."},{"key":"67508_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.25259\/IJMS_159_2020","volume":"73","author":"V Mishra","year":"2021","unstructured":"Mishra, V. & Balasubramaniam, G. Urinary bladder cancer and its associated factors: An epidemiological overview. IJMS 73, 239\u2013248 (2021).","journal-title":"IJMS"},{"key":"67508_CR5","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia, C. et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 135, 584\u2013590 (2022).","journal-title":"Chin Med J (Engl)"},{"key":"67508_CR6","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.21037\/atm-20-2108","volume":"8","author":"Y Zang","year":"2020","unstructured":"Zang, Y., Li, X., Cheng, Y., Qi, F. & Yang, N. An overview of patients with urothelial bladder cancer over the past two decades: a Surveillance, Epidemiology, and End Results (SEER) study. Ann. Transl. Med. 8, 1587\u20131587 (2020).","journal-title":"Ann. Transl. Med."},{"key":"67508_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nrurol.2015.12","volume":"12","author":"A Sanchez","year":"2015","unstructured":"Sanchez, A. & Wszolek, M. F. Quality of life in patients with non-muscle-invasive bladder cancer. Nat. Rev. Urol. 12, 186\u2013188 (2015).","journal-title":"Nat. Rev. Urol."},{"key":"67508_CR8","doi-asserted-by":"publisher","first-page":"7745","DOI":"10.7150\/thno.77281","volume":"12","author":"Y Liang","year":"2022","unstructured":"Liang, Y. et al. Single-cell atlases link macrophages and CD8+ T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma. Theranostics 12, 7745\u20137759 (2022).","journal-title":"Theranostics"},{"key":"67508_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajur.2021.10.002","volume":"10","author":"V Chalfant","year":"2023","unstructured":"Chalfant, V., Blute, M. L. & Silberstein, P. Treatment trends of muscle invasive bladder cancer: Evidence from the surveillance, epidemiology, and end results database, 1988 to 2013. Asian J. Urol. 10, 9\u201318 (2023).","journal-title":"Asian J. Urol."},{"key":"67508_CR10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.21037\/tau-20-960","volume":"10","author":"J Tian","year":"2021","unstructured":"Tian, J. et al. Population-based outcome of muscle-invasive bladder cancer following radical cystectomy: who can benefit from adjuvant chemotherapy?. Transl. Androl. Urol. 10, 356\u2013373 (2021).","journal-title":"Transl. Androl. Urol."},{"key":"67508_CR11","doi-asserted-by":"publisher","first-page":"7201","DOI":"10.3390\/ijms22137201","volume":"22","author":"I-H Kim","year":"2021","unstructured":"Kim, I.-H. & Lee, H.-J. Perioperative systemic treatment for muscle-invasive bladder cancer: Current evidence and future perspectives. Int. J. Mol. Sci. 22, 7201 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"67508_CR12","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1078-0432.CCR-15-1208","volume":"22","author":"HS Kim","year":"2016","unstructured":"Kim, H. S., Jeong, C. W., Kwak, C., Kim, H. H. & Ku, J. H. Pathological T0 following cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer: A network meta-analysis. Clin. Cancer Res. 22, 1086\u20131094 (2016).","journal-title":"Clin. Cancer Res."},{"key":"67508_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ajur.2015.04.016","volume":"2","author":"K Li","year":"2015","unstructured":"Li, K. et al. Current status of diagnosis and treatment of bladder cancer in China: Analyses of Chinese bladder cancer consortium database. Asian J. Urol. 2, 63\u201369 (2015).","journal-title":"Asian J. Urol."},{"key":"67508_CR14","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"67508_CR15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1200\/JCO.2022.40.6_suppl.521","volume":"40","author":"T Csoszi","year":"2022","unstructured":"Csoszi, T. et al. First-line pembrolizumab in advanced urothelial carcinoma: Clinical parameters associated with efficacy in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-361 trials. JCO 40, 521\u2013521 (2022).","journal-title":"JCO"},{"key":"67508_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.4103\/iju.IJU_540_20","volume":"37","author":"A Chatterjee","year":"2021","unstructured":"Chatterjee, A. et al. Perioperative therapy in muscle invasive bladder cancer. Indian J. Urol. 37, 226\u2013233 (2021).","journal-title":"Indian J. Urol."},{"key":"67508_CR17","doi-asserted-by":"publisher","first-page":"6546","DOI":"10.21037\/tcr.2020.01.36","volume":"9","author":"HH Lee","year":"2020","unstructured":"Lee, H. H. & Ham, W. S. Perioperative immunotherapy in muscle-invasive bladder cancer. Transl. Cancer Res. 9, 6546\u20136553 (2020).","journal-title":"Transl. Cancer Res."},{"key":"67508_CR18","doi-asserted-by":"publisher","first-page":"1861737","DOI":"10.1080\/2162402X.2020.1861737","volume":"10","author":"S Cheng","year":"2021","unstructured":"Cheng, S. et al. Prognostic role of stromal tumor-infiltrating lymphocytes in locally advanced upper tract urothelial carcinoma: A retrospective multicenter study (TSU-02 study). Oncoimmunology 10, 1861737 (2021).","journal-title":"Oncoimmunology"},{"key":"67508_CR19","doi-asserted-by":"publisher","first-page":"e656","DOI":"10.3747\/co.27.6437","volume":"27","author":"J Huang","year":"2020","unstructured":"Huang, J. & Teng, X. Expression of PD-L1 for predicting response to immune checkpoint inhibitors in metastatic urothelial carcinoma: A systematic review and meta-analysis. Curr. Oncol. 27, e656\u2013e663 (2020).","journal-title":"Curr. Oncol."},{"key":"67508_CR20","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.18.01148","volume":"36","author":"A Necchi","year":"2018","unstructured":"Necchi, A. et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, Phase II Study. J Clin Oncol 36, 3353\u20133360 (2018).","journal-title":"J Clin Oncol"},{"key":"67508_CR21","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin, D. F. et al. Adjuvant Nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102\u20132114 (2021).","journal-title":"N. Engl. J. Med."},{"key":"67508_CR22","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles, T. et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): A randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 21, 1574\u20131588 (2020).","journal-title":"Lancet Oncol."},{"key":"67508_CR23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00428-018-2445-7","volume":"474","author":"S Savic-Prince","year":"2019","unstructured":"Savic-Prince, S. & Bubendorf, L. Predictive potential and need for standardization of PD-L1 immunohistochemistry. Virchows Arch. 474, 475\u2013484 (2019).","journal-title":"Virchows Arch."},{"key":"67508_CR24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/path.5230","volume":"247","author":"G Sjodahl","year":"2019","unstructured":"Sjodahl, G., Jackson, C. L., Bartlett, J. M., Siemens, D. R. & Berman, D. M. Molecular profiling in muscle-invasive bladder cancer: More than the sum of its parts. J. Pathol. 247, 563\u2013573 (2019).","journal-title":"J. Pathol."},{"key":"67508_CR25","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma, P. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. Lancet Oncol. 18, 312\u2013322 (2017).","journal-title":"Lancet Oncol."},{"key":"67508_CR26","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"67508_CR27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt, J. et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 22, 525\u2013537 (2021).","journal-title":"Lancet Oncol."},{"key":"67508_CR28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","volume":"77","author":"A Necchi","year":"2020","unstructured":"Necchi, A. et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur. Urol. 77, 439\u2013446 (2020).","journal-title":"Eur. Urol."},{"key":"67508_CR29","doi-asserted-by":"publisher","first-page":"527385","DOI":"10.3389\/fonc.2020.527385","volume":"10","author":"B Kim","year":"2020","unstructured":"Kim, B., Lee, C., Kim, Y. A. & Moon, K. C. PD-L1 expression in muscle-invasive urinary bladder urothelial carcinoma according to basal\/squamous-like phenotype. Front. Oncol. 10, 527385 (2020).","journal-title":"Front. Oncol."},{"key":"67508_CR30","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/annonc\/mdv009","volume":"26","author":"J Bellmunt","year":"2015","unstructured":"Bellmunt, J. et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann. Oncol. 26, 812\u2013817 (2015).","journal-title":"Ann. Oncol."},{"key":"67508_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13578-018-0232-4","volume":"8","author":"F Tang","year":"2018","unstructured":"Tang, F. & Zheng, P. Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1\/PD-L1 blockade mediated cancer immunotherapy?. Cell Biosci. 8, 34 (2018).","journal-title":"Cell Biosci."},{"key":"67508_CR32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/cas.13887","volume":"110","author":"B Wang","year":"2019","unstructured":"Wang, B. et al. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. Cancer Sci. 110, 489\u2013498 (2019).","journal-title":"Cancer Sci."},{"key":"67508_CR33","doi-asserted-by":"publisher","first-page":"e1015","DOI":"10.1016\/j.clgc.2018.05.015","volume":"16","author":"R Pichler","year":"2018","unstructured":"Pichler, R. et al. Prognostic value of testing PD-L1 expression after radical cystectomy in high-risk patients. Clin. Genitourin. Cancer 16, e1015\u2013e1024 (2018).","journal-title":"Clin. Genitourin. Cancer"},{"key":"67508_CR34","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes, J. A. et al. European Association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines. Eur. Urol. 79, 82\u2013104 (2021).","journal-title":"Eur. Urol."},{"key":"67508_CR35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.currproblcancer.2014.06.001","volume":"38","author":"JC Park","year":"2014","unstructured":"Park, J. C., Citrin, D. E., Agarwal, P. K. & Apolo, A. B. Multimodal management of muscle invasive bladder cancer. Curr. Probl. Cancer 38, 80\u2013108 (2014).","journal-title":"Curr. Probl. Cancer"},{"key":"67508_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.urology.2013.07.072","volume":"83","author":"HB Zaid","year":"2014","unstructured":"Zaid, H. B. et al. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: Results from the national cancer database. Urology 83, 75\u201380 (2014).","journal-title":"Urology"},{"key":"67508_CR37","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.eururo.2012.01.039","volume":"61","author":"M Burger","year":"2012","unstructured":"Burger, M., Mulders, P. & Witjes, W. Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: Results of a feasibility questionnaire. Eur. Urol. 61, 1070\u20131071 (2012).","journal-title":"Eur. Urol."},{"key":"67508_CR38","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s00262-019-02340-w","volume":"68","author":"BC Holland","year":"2019","unstructured":"Holland, B. C. et al. Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy. Cancer Immunol. Immunother. 68, 991\u2013997 (2019).","journal-title":"Cancer Immunol. Immunother."},{"key":"67508_CR39","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.2147\/CMAR.S176937","volume":"11","author":"X Ding","year":"2019","unstructured":"Ding, X. et al. Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: A meta-analysis. Cancer Manag. Res. 11, 4171\u20134184 (2019).","journal-title":"Cancer Manag. Res."},{"key":"67508_CR40","first-page":"404","volume":"11","author":"IA Nechifor-Boil\u0103","year":"2021","unstructured":"Nechifor-Boil\u0103, I. A. et al. PD-L1 expression in muscle invasive urothelial carcinomas as assessed via immunohistochemistry: Correlations with specific clinical and pathological features, with emphasis on prognosis after radical cystectomy. Life (Basel) 11, 404 (2021).","journal-title":"Life (Basel)"},{"key":"67508_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejso.2013.08.023","volume":"40","author":"E Xylinas","year":"2014","unstructured":"Xylinas, E. et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur. J. Surg. Oncol. 40, 121\u2013127 (2014).","journal-title":"Eur. J. Surg. Oncol."},{"key":"67508_CR42","doi-asserted-by":"publisher","first-page":"66849","DOI":"10.18632\/oncotarget.19913","volume":"8","author":"R Pichler","year":"2017","unstructured":"Pichler, R. et al. PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. Oncotarget 8, 66849\u201366864 (2017).","journal-title":"Oncotarget"},{"key":"67508_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-022-00218-z","author":"S Chhaya","year":"2023","unstructured":"Chhaya, S. et al. Role of perioperative immune checkpoint inhibitors in muscle invasive bladder cancer. Oncol. Ther. https:\/\/doi.org\/10.1007\/s40487-022-00218-z (2023).","journal-title":"Oncol. Ther."},{"key":"67508_CR44","doi-asserted-by":"publisher","first-page":"20495","DOI":"10.1038\/s41598-022-23319-1","volume":"12","author":"Y-J Kang","year":"2022","unstructured":"Kang, Y.-J. et al. A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours. Sci. Rep. 12, 20495 (2022).","journal-title":"Sci. Rep."},{"key":"67508_CR45","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1172\/JCI80008","volume":"125","author":"MM Gubin","year":"2015","unstructured":"Gubin, M. M., Artyomov, M. N., Mardis, E. R. & Schreiber, R. D. Tumor neoantigens: Building a framework for personalized cancer immunotherapy. J. Clin. Investig. 125, 3413\u20133421 (2015).","journal-title":"J. Clin. Investig."},{"key":"67508_CR46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe, A. H. & Pauken, K. E. The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 18, 153\u2013167 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"67508_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41065-020-00165-7","volume":"158","author":"Z Chen","year":"2021","unstructured":"Chen, Z. et al. Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes. Hereditas 158, 1 (2021).","journal-title":"Hereditas"},{"key":"67508_CR48","doi-asserted-by":"publisher","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","volume":"3","author":"T Powles","year":"2017","unstructured":"Powles, T. et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: Updated results from a phase 1\/2 open-label Study. JAMA Oncol 3, e172411 (2017).","journal-title":"JAMA Oncol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67508-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67508-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67508-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T10:02:41Z","timestamp":1721469761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67508-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["67508"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-67508-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,20]]},"assertion":[{"value":"8 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. This study was approved by the Ethics Committee of the respective study sites.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}},{"value":"Informed consent was obtained from all subjects included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"16753"}}